Oscar Health Gets $400 Million And A $2.7 Billion Valuation from Fidelity
Oscar Health Insurance just received a massive cash injection from one of the biggest and most conservative investors in the business. — Today Oscar announced that mutual fund giant Fidelity led a $400 million investment … Tweets: @jasonlk , @howardlindzon and @oscarhealth Tweets: Jason M. Lemkin / @jasonlk : They may do a few mark-downs here and there. But bless these Fidelity guys for staying in the game! http://twitter.com/... @howardlindzon : Which means write down imminent ? ... http://www.forbes.com/... Oscar / @oscarhealth : “Oscar's had amazing execution in a business that is highly complex, regulated, and competitive & capital intensive” http://www.forbes.com/...
Context & Ripple Effects
Oscar's valuation has climbed fast through successive raises: last April's $145M round priced it at $1.5B, and by September Google Capital paid up at $1.75B. Today's $400M from Fidelity at $2.7B continues that ladder — but the lead investor is the story.
Fidelity is one of the most conservative allocators in the business, and its willingness to anchor a round in a consumer-facing health insurer reads as institutional validation of Oscar's direct-to-consumer model. The Twitter reaction captured in the piece (@jasonlk praising Fidelity for staying in the game, @howardlindzon asking whether a write-down is imminent) shows investors already debating how these marks will age.
First-order effects
- Oscar gains $400M of fresh capital and a $2.7B mark — roughly a 55% step-up from Google Capital's September price — extending its runway to keep building out its insurance stack.
- Fidelity takes a large, visible position in a pre-IPO health insurer, putting its own fund marks directly exposed to Oscar's underwriting performance.
Second-order effects
- Other mutual-fund and pension-scale investors now have a conservative-peer precedent for entering late-stage digital health deals, tightening competition for allocations in rounds like Oscar's next ones.
- Rival insurers and health-tech startups face a better-funded Oscar and must either raise on similar terms or differentiate on cost of care rather than growth spend.
Third-order effects
- If the pattern holds — repeated nine-figure raises at rising marks — the endgame is a public listing, which is where this trajectory eventually landed when Oscar priced its IPO at $39 per share, raising $1.44B at a $9.5B valuation.
- The episode foreshadows the broader blurring of mutual-fund and venture capital: crossover firms marking private positions quarterly means valuations like Oscar's get tested publicly long before any IPO, write-down risk included.
The trend: Crossover capital from conservative mutual funds is increasingly setting the price of private health-insurance disruptors, pulling their valuations into public-market scrutiny years before they list.